Target intelligence / Profile preview

Cholesterol excretion

Molecular classification
Other (process/physiological pathway), Involves enzymes (e.g., CYP7A1 for bile acid synthesis), Involves transporters (e.g., ABCG5/ABCG8, ABCA1/ABCG1)
01

Overview

Cholesterol excretion refers to the set of physiological processes by which excess cholesterol is removed from the body. The main routes are conversion into bile acids in the liver followed by biliary secretion into the intestine and subsequent fecal elimination. Another significant route is transintestinal cholesterol excretion (TICE), where enterocytes secrete free cholesterol directly into the gut lumen independently from bile. Reverse cholesterol transport involves high-density lipoproteins collecting peripheral tissue cholesterol and delivering it back to the liver for disposal via these routes. Multiple proteins—including hepatic enzymes like CYP7A1, ATP-binding cassette transporters such as ABCA1/G5/G8—are essential components facilitating these processes[1][3]. Impaired function at any step can contribute to hypercholesterolemia and cardiovascular risk. In summary, "cholesterol excretion" should be considered as a complex biological pathway/process rather than an individual druggable target or receptor[1][3].

Other names
Cholesterol eliminationFecal cholesterol lossBiliary cholesterol secretionTransintestinal cholesterol excretion (TICE)Reverse cholesterol transport (RCT)
02

Mechanism of action

Drugs influencing cholesterol excretion act by inhibiting intestinal absorption of dietary/biliary cholesterol (e.g., ezetimibe) or by promoting fecal loss through binding bile acids in the gut (e.g., bile acid sequestrants). These mechanisms modulate steps within the overall cholesterol excretion pathway.

03

Biological functions

Lipid homeostasisCholesterol metabolismDetoxification/excretion
04

Disease associations

Cardiovascular diseaseGallstone disease
05

Safety considerations

Gastrointestinal side effects (from drugs increasing fecal sterol loss)Fat-soluble vitamin malabsorption (from drugs increasing fecal sterol loss)
06

Interacting drugs

Ezetimibe

1 more in the full profile.

07

Biomarkers

Fecal sterol outputPlasma HDL-cholesterol levels (reflecting RCT activity)

Beyond the preview

Go deeper on Cholesterol excretion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cholesterol excretion.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call